National Bank of Canada
CRSP icon

National Bank of Canada’s CRISPR Therapeutics CRSP Stock Holding History

National Bank of Canada’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,890
Closed -$15.2M – 3011
2025
Q4 		$15.2M Sell
2,890
-1,735
-38% -$104K 0.01% 593
2025
Q3 		$30M Sell
4,625
-5,662
-55% -$325K 0.03% 392
2025
Q2 		$50M Buy
+10,287
New +$398K 0.05% 304

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

National Bank of Canada's CRSP Position: Q2 2026 in Review

National Bank of Canada reduced its CRISPR Therapeutics (CRSP) stake by 0.37% in Q2 2026, selling an estimated $264 and leaving 1,356 shares worth $73.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1919.

National Bank of Canada first reported a position in CRSP in Q4 2021 and has held it in 16 quarters since. The position peaked at $35.8M in Q2 2025. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • National Bank of Canada held 1,356 shares of CRISPR Therapeutics worth $73.9K as of Q2 2026.
  • National Bank of Canada sold 5 CRISPR Therapeutics shares in Q2 2026, an estimated $264.
  • CRISPR Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q2 2026, its #1919 holding.
  • National Bank of Canada first reported a position in CRISPR Therapeutics in Q4 2021 and has held it in 16 quarters since.
  • National Bank of Canada's CRISPR Therapeutics position peaked at $35.8M in Q2 2025.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.